Paradise is included in the same Central Social Insurance Medical Council General schedule as Symplicity. The council advises Japan’s Ministry of Health, Labour and Welfare (MHLW). Medtronic announced earlier this month that the MHLW had approved reimbursement for Symplicity Spyral.
In a statement shared by a Recor spokesperson, the U.S.-based subsidiary of Tokyo-based Otsuka said: “The information is already publicly available, and we will announce formally on March 2.”
The news comes more than five months after the country’s Pharmaceuticals and Medical Devices Agency (PMDA) approved Paradise and Symplicity Spyral.
Paradise and Symplicity Spyral have both been U.S. FDA approved since late 2023, with a CMS National Coverage Determination (NCD) in 2025 supporting reimbursement. Both systems are delivered in minimally invasive procedures to denervate the sympathetic nerves surrounding the renal arteries. Paradise uses ultrasound energy, while Symplicity Spyral uses RF ablation.
